{"product_id":"alny-swot-analysis","title":"(ALNY) Alnylam Pharmaceuticals, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidate Every Claim with the Complete Sources File\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Alnylam Pharmaceuticals, Inc. SWOT Analysis summarizes the company’s core strengths, weaknesses, opportunities, and threats to help with research, strategy, investing, or planning, and this page already includes a real preview\/sample of the analysis so you can review style and substance before buying; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 approved therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam has 3 marketed therapies: ONPATTRO, GIVLAARI, and OXLUMO. That gives it recurring product revenue and real-world proof that RNAi can work in patients, not just in labs. It also lowers dependence on any single asset, which helps reduce pipeline risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi technology leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. is built on RNAi, a differentiated therapy that can silence disease-causing genes at the source. It has 4 approved RNAi medicines, which shows real platform depth and makes simple copycat competition hard. That same science also supports expansion across kidney, cardio, and rare-disease programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad pipeline across 7+ programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam is advancing more than 7 programs across cardiometabolic disease, HBV, AAT deficiency, hypertension, hemophilia, and complement-mediated disorders. That breadth improves the odds that at least one asset reaches approval and helps offset setbacks in any single indication. It also spreads R\u0026amp;D risk across several markets, instead of depending on one lead candidate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLate-stage assets in Phase 3\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc.'s late-stage pipeline is a clear strength: AMVUTTRA (vutrisiran) already won FDA approval in March 2025 for ATTR cardiomyopathy, and its HELIOS-B phase 3 trial enrolled 654 patients. Programs this far along are much closer to filings and launch than early discovery assets, so they can add near-term commercial upside if results hold.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePhase 3 assets reduce regulatory wait time.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eVutrisiran already reached a 2025 label expansion.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePositive pivotal data can drive faster growth.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnered development model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam's partnered development model is a clear strength: it works with 6 named partners, including Regeneron, Sanofi Genzyme, Novartis, Vir Biotechnology, Ionis, and PeptiDream. These alliances share R\u0026amp;D costs, widen access to new targets, and help move RNAi programs into more markets. External partners also act as third-party validation for the platform.\u003c\/p\u003e\n\u003cp\u003eThat matters in a high-burn drug pipeline, where one success can take years and many trials. Shared work can keep capital focused on late-stage assets while still expanding the target base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShares development risk and cost\u003c\/li\u003e\n\u003cli\u003eExpands reach into new markets\u003c\/li\u003e\n\u003cli\u003eSignals external scientific validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam’s Proven RNAi Platform Has Real Growth Catalysts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam has 4 approved RNAi medicines, so its platform is already proven in patients and not just in labs. AMVUTTRA’s 2025 FDA label expansion in ATTR cardiomyopathy adds near-term growth, and HELIOS-B enrolled 654 patients, showing late-stage depth. Its 6 named partners also spread cost and risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved medicines\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHELIOS-B enrollment\u003c\/td\u003e\n\u003ctd\u003e654\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed partners\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Alnylam Pharmaceuticals, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick SWOT snapshot for Alnylam Pharmaceuticals, Inc. to simplify strategic decisions and highlight key risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography of primary industry reports, regulatory filings, and peer-reviewed studies to speed due diligence and verify Alnylam's market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited marketed portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. still has a narrow marketed base: its approved drugs are Onpattro, Givlaari, Oxlumo, and Amvuttra, so a miss in any one product can quickly hurt sales. In the latest reported fiscal year, product revenue came from this small lineup, which keeps concentration risk high. That is a thinner commercial footprint than larger diversified biopharma peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy R and D dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc.’s value still hinges on clinical and regulatory wins; one late-stage miss can reset the story. RNAi programs are slow and costly, and Alnylam has spent over $1B a year on R\u0026amp;D, which can pressure margins and cash before new launches scale. With FY2024 revenue around $2.2B, heavy R\u0026amp;D remains its key weakness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in rare diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. is still heavily tied to rare and ultra-rare diseases, so its revenue base is narrower than that of companies selling into large primary-care markets. In 2024, net product revenues were about $2.2 billion, but growth still depends on premium pricing and moving beyond niche indications like ONPATTRO, GIVLAARI, and AMVUTTRA.\u003c\/p\u003e\n\u003cp\u003eThat makes the portfolio medically strong but commercially concentrated, so any slower uptake or reimbursement pushback can matter more than it would in broader markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline execution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. has 4 marketed drugs, but much of its growth still rests on investigational assets that have not proved commercial demand. A setback in Phase 2 or Phase 3 can erase expected value fast, especially when the company is still trying to turn pipeline depth into new approvals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 approved products do not remove pipeline risk.\u003c\/li\u003e\n\u003cli\u003eLate-stage trial failures hit valuation hard.\u003c\/li\u003e\n\u003cli\u003eFuture growth depends on approvals, not hopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis makes execution a key weakness: every delay, safety issue, or weak efficacy signal can push revenue farther out and raise pressure on R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. relies on multiple alliances, so shared control and milestone-based economics can cut into upside versus wholly owned products. That matters when cash flow depends on partner execution, because revenue is split and development choices can slow across 2025–2026 programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShared control slows decisions\u003c\/li\u003e\n\u003cli\u003eMilestones delay cash inflow\u003c\/li\u003e\n\u003cli\u003eRevenue splits reduce margins\u003c\/li\u003e\n\u003cli\u003eMore partners add launch friction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam’s Heavy Reliance on Just Four Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. is still exposed to concentration risk: its marketed base is only Onpattro, Givlaari, Oxlumo, and Amvuttra, so any slowdown in one drug can hit sales fast. FY2024 net product revenue was about $2.2 billion, while R\u0026amp;D stayed above $1 billion, so the business still leans on costly pipeline wins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct concentration\u003c\/td\u003e\n\u003ctd\u003e4 marketed drugs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003e~$2.2B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D burden\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAlnylam Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it highlights Alnylam Pharmaceuticals' strengths, weaknesses, opportunities, and threats with concise, actionable insight. Buy to unlock the complete, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eATTR expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eATTR expansion is a major upside for Alnylam Pharmaceuticals, Inc.: patisiran and vutrisiran already target transthyretin amyloidosis, and vutrisiran’s ATTR-CM reach opens a bigger market. ATTR cardiomyopathy is still underdiagnosed, with an estimated 100,000+ U.S. patients, so each label gain can lift both treated volume and longer-term revenue. That makes this a high-value, high-unmet-need area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHypertension market entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZilebesiran gives Alnylam Pharmaceuticals, Inc. a shot at hypertension, a market with about 1.3 billion adults worldwide living with high blood pressure. Even small efficacy gains could matter because a 6-month injectable could reach patients who struggle with daily pills. That makes it one of Alnylam Pharmaceuticals, Inc. biggest moves beyond rare disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHBV and liver disease programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALN-HBV02 and ALN-HSD target huge liver-disease markets. WHO says about 254 million people live with chronic hepatitis B, while MASH, the newer term for NASH-related disease, affects about 5% of adults worldwide. Positive data could push Alnylam into far larger patient pools and revenue potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpanded indication approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. can grow OXLUMO and other RNAi assets by adding broader labels, such as advanced PH1 and recurrent kidney stones, without funding a new drug from scratch. That matters because label expansion is usually far cheaper than building a new program and can lift peak sales from the same asset base. In 2025, Alnylam Pharmaceuticals, Inc. said its total revenue was above $2 billion, so even modest label gains can move the top line.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader labels can raise peak sales\u003c\/li\u003e\n\u003cli\u003eCapital use stays relatively low\u003c\/li\u003e\n\u003cli\u003ePH1 gaps can expand the addressable pool\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCNS and ocular RNAi targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with Regeneron and others give Alnylam Pharmaceuticals, Inc. a path into CNS and ocular RNAi targets, markets far beyond its 4 approved medicines and multi-billion-dollar rare-disease base. If these programs work, they could turn RNAi from a niche platform into a broader drug engine and support higher long-term revenue optionality.\u003c\/p\u003e\n\u003cp\u003eThat matters because CNS and eye diseases are large, under-served areas where local delivery can make RNAi practical. Success would diversify Alnylam Pharmaceuticals, Inc.'s franchise, reduce dependence on current rare-disease products, and strengthen platform credibility in 2025\/2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCNS and ocular targets expand RNAi reach.\u003c\/li\u003e\n\u003cli\u003eRegeneron access helps de-risk development.\u003c\/li\u003e\n\u003cli\u003eSuccess would broaden revenue and credibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam’s Big Upside: ATTR, Hypertension, HBV, and MASH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. has clear upside in ATTR, where ATTR-CM remains underdiagnosed and label gains can expand treated volume fast. Zilebesiran opens a far larger hypertension market, and ALN-HBV02 plus ALN-HSD could reach hepatitis B and MASH populations measured in the hundreds of millions. With 2025 revenue above $2 billion, even small label wins can move sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eATTR expansion\u003c\/td\u003e\n\u003ctd\u003e100,000+ U.S. ATTR-CM patients\u003c\/td\u003e\n\u003ctd\u003eBroader labels lift volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZilebesiran\u003c\/td\u003e\n\u003ctd\u003e1.3 billion with hypertension\u003c\/td\u003e\n\u003ctd\u003eMoves beyond rare disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALN-HBV02, ALN-HSD\u003c\/td\u003e\n\u003ctd\u003e254 million HBV; 5% adults with MASH\u003c\/td\u003e\n\u003ctd\u003eHuge new revenue pools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLate-stage readouts can still erase years of spend, and for Alnylam Pharmaceuticals, Inc. that risk matters because its growth depends on a pipeline of RNAi assets. A Phase 3 miss can cut expected revenue, delay label expansion, and shake investor confidence fast. Pipeline-heavy biotechs often trade on trial data, so even one setback can hit valuation hard.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition from alternative modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompetition from alternative modalities is a real threat because gene editing, monoclonal antibodies, small molecules, and other RNA-based drugs all chase the same targets. In many programs, a rival that offers 1-dose or less frequent dosing, better safety, or stronger efficacy can take share fast. That pressure is high in both rare diseases and larger markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty and rare-disease drugs face tight payer review, and Alnylam Pharmaceuticals, Inc. can see slower uptake when launch prices trigger step edits or prior authorization. High-cost therapies often get pushed into stricter rebate talks, which can delay access and hurt pharmacy fill rates. If reimbursement stays tight, future launches like this can miss expected adoption even when clinical data are strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and safety scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRNAi therapies face tight FDA and EMA scrutiny on safety, CMC, and batch consistency. For Alnylam Pharmaceuticals, Inc., even one adverse event signal or a filing delay can push a launch back by 6-12 months and slow label expansion across a pipeline that, as of 2025, includes 5 approved medicines.\u003c\/p\u003e\n\u003cp\u003eThat matters because regulatory setbacks can hit both timing and cash flow, not just headlines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict CMC checks can delay approvals.\u003c\/li\u003e\n\u003cli\u003eSafety signals can pause filings.\u003c\/li\u003e\n\u003cli\u003eOne hold can shift multiple programs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and partner dependency risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. depends on patent protection and licensed technologies, so a lost dispute or tougher royalty terms could quickly pressure margins. It also uses partners for some programs, which can delay execution and weaken control over strategy. That risk matters because even one key collaboration shift can affect multiple pipeline assets at once.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIP loss can cut pricing power.\u003c\/li\u003e\n\u003cli\u003eLicensing terms can squeeze economics.\u003c\/li\u003e\n\u003cli\u003ePartners add execution risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam’s Growth Faces Trial, Payer, and Patent Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. still faces big threat from trial misses, because its 2025 revenue depended on 4 approved RNAi drugs and a deep pipeline. Payer pushback, FDA\/EMA delays, and patent or royalty disputes can slow launches and squeeze margins. Rival therapies that win on dosing or safety can take share fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline setback\u003c\/td\u003e\n\u003ctd\u003eCan hit valuation fast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer pressure\u003c\/td\u003e\n\u003ctd\u003eSlows uptake and access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP or partner loss\u003c\/td\u003e\n\u003ctd\u003eSqueezes margins and control\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233980850441,"sku":"alny-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/alny-swot-analysis.webp?v=1785710379","url":"https:\/\/dcfanalyst.com\/products\/alny-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}